Capital has not disappeared; it has become selective

SIDBI’s research finds that medium enterprises face the highest credit gap — around 29% — precisely when they need capital to move from a proven business to a larger institution.
On the equity side, capital is also concentrating in fewer, larger and better-prepared opportunities. The common conclusion is that a good business is no longer enough. The business must be legible to someone who did not build it.

Working capital can consume the growth plan

Receivables are one of the quietest constraints on MSME growth. A company can be profitable on paper and still lack the cash to accept a large order, fund inventory, invest in certification or hire senior leadership.
Growth capital intended for expansion often gets diverted into operating gaps because collection discipline, customer terms and working-capital financing were not redesigned for scale.

Readiness is the most fixable constraint

Lenders, investors and strategic partners need a coherent view of the business: reliable financials, customer concentration, unit economics, governance, growth priorities, capital use and execution ownership. Many promoter-led companies possess strong underlying economics but present them through fragmented information and founder-held context. The case for the business has never been built in a form an outsider can evaluate confidently.

QUESTIONS WORTH ASKING
• Could an external lender or investor understand the business without the promoter translating every
number?
• How much working capital would be required if revenue grew 30% next year?
• What percentage of revenue depends on the founder’s direct relationships?
• Is there a current data room, governance story and defensible use-of-funds plan?

DANTAYA’S VIEW
Businesses rarely stall because the market has permanently rejected them. More often, they reach the market’s door unprepared for the questions it was always going to ask. Readiness can be built in months — and it changes the terms of every conversation that follows.

The boundary of reporting is moving

Large listed companies are increasingly expected to assess and disclose material ESG information across their value chains. That creates a practical consequence for private suppliers: customer procurement and sustainability teams will ask for data that many MSMEs have never collected systematically. The request may cover energy use, emissions, water, waste, workforce practices, safety, traceability and governance. It often arrives as a spreadsheet with a deadline, not as a strategic discussion.

CBAM has moved from preparation to operation

The European Union’s Carbon Border Adjustment Mechanism entered its definitive phase in 2026. It initially covers carbon-intensive sectors such as iron and steel, aluminium, cement, fertilisers, electricity and hydrogen.
Even businesses outside the directly covered categories may feel the effect through customers that need reliable embedded-emissions information from their suppliers. Carbon data is becoming part of commercial documentation.

Readiness can influence vendor decisions

A supplier that responds quickly with credible data appears easier to retain, audit and scale. A supplier that cannot provide basic information may look like a future compliance burden — even when product quality is strong.
The objective is not to build an elaborate sustainability department immediately. It is to establish ownership, boundaries, source records, calculation methods and a repeatable data process before the first urgent request.

QUESTIONS WORTH ASKING
• Which major customers already have BRSR or international reporting obligations?
• Who owns energy, emissions, waste, safety and workforce data inside the business?
• Can the company trace the source of every material number it reports?
• Could ESG readiness become part of our vendor-positioning and financing story?

DANTAYA’S VIEW
ESG becomes commercially useful when it is treated as data and operating discipline, not as a presentation. Basic readiness costs far less when built deliberately than when assembled under a customer deadline.

The money is real — and selective

Private-market funding is increasingly concentrated in fewer, larger transactions. AI infrastructure, data centres, deep technology and businesses with visible commercial traction are receiving serious attention. At the same time, investors are more sceptical of products that amount to a thin layer over another company’s model.
This does not mean every successful AI company must build a foundation model. It means the business must own something that is difficult to replicate: data, workflow, distribution, domain knowledge, regulatory position, customer integration or execution at scale.

Enterprise buyers are asking the same question

The investor’s question and the enterprise buyer’s question are converging: why will this remain valuable when the underlying models become cheaper, faster and more capable?
A strong answer may be proprietary data accumulated through use, deep integration into a mission-critical workflow, measurable outcomes, a compliance layer, or distribution that cannot be purchased quickly. “We use AI” is not a moat. In many categories it is already a minimum expectation.

IT services face the mirror image

Routine technology work is being repriced because customers assume AI will reduce effort. Whether that assumption is fully correct is less important than the fact that it now shapes procurement.
Services firms protecting margins are moving away from selling headcount and toward selling outcomes, domain expertise, intellectual property, managed platforms and responsibility for a business metric.

QUESTIONS WORTH ASKING
• What part of our value survives if the underlying model improves dramatically?
• Which proprietary data or workflow advantage grows every time a customer uses the product?
• Are we selling technology activity or a measurable business outcome?
• Could a well-funded competitor reproduce the product and distribution within 18 months?

DANTAYA’S VIEW
The next phase of AI will reward companies that are commercially durable, not merely technically current. Founders should build the moat and the revenue engine at the same time — before fundraising or enterprise procurement exposes the gap.

A reprieve, not certainty

Recent U.S. pharmaceutical tariff measures focus primarily on patented and branded products, while generic medicines remain excluded at the time of writing. Since generics form the bulk of India’s pharmaceutical exports to the United States, the immediate impact on much of the sector is limited. The larger issue is not today’s exemption. It is the uncertainty around future policy, pricing pressure and reshoring incentives. A business that treats temporary relief as a permanent assumption is effectively outsourcing strategy to a policy decision it does not control.

Concentration is the underlying risk

For companies with material U.S. exposure, the relevant board question is not whether the market should be abandoned. It is whether the company has enough strategic options if margins, tariffs or buyer behaviour change.
Those options may include complex generics, specialty products, CDMO relationships, licensing structures,
selective U.S. manufacturing partnerships, or stronger channels in the UK, Europe, Africa, Latin America and
other regulated or semi-regulated markets.

API dependence belongs in the same conversation

Market concentration and input concentration are two sides of the same strategic risk. Indian pharmaceutical businesses continue to depend materially on imported APIs and intermediates. A company can diversify customers and remain exposed if its critical inputs still come from a narrow supply base. The appropriate response is rarely complete self-sufficiency. It is a deliberate map of critical dependencies, alternatives, inventory economics, domestic sourcing potential and partnership options.

QUESTIONS WORTH ASKING
• What percentage of revenue and profit depends on the U.S. market?
• Which products would remain attractive if tariff or pricing pressure increased materially?
• Could another geography replace even 15–20% of U.S.-linked revenue within 18 months?
• Which APIs or intermediates have no commercially realistic second source?

DANTAYA’S VIEW
Relief creates time. The best use of that time is not to predict policy; it is to create options. Diversification, partnerships and supply resilience take longer to build than most boards expect.

The opportunity behind the headline

Manufacturing discussions frequently begin with incentive schemes. Incentives can help, but they are not a growth strategy. The more important second-order effect is the supplier ecosystem that follows every serious anchor investment.

Semiconductor, electronics, mobility and advanced-manufacturing projects require a long tail of precision components, enclosures, packaging, tooling, testing, maintenance and logistics. These requirements do not end when an incentive programme closes. Once a supplier is qualified and performs reliably, purchase orders can compound for years.

Qualification is commercial, not ceremonial

Large manufacturers qualify vendors against quality systems, delivery performance, financial capacity, process control, traceability and the ability to increase output without disrupting supply. Relationships may open a door, but they do not substitute for operating evidence.

The promoters who win these slots usually begin preparing well before the opportunity becomes public. They clean up financial reporting, secure the right certifications, strengthen quality documentation and build a credible plan for capacity expansion.

The financing question arrives before the order

Vendor qualification often asks a difficult question: can the business commit capacity before demand is fully contracted? That is not merely a production decision. It is a capital-structure and risk-allocation decision.

A poorly timed expansion can strain debt service and working capital. A delayed expansion can lose the qualification window. The answer lies in sequencing: evidence of demand, phased capacity, appropriate debt tenor, promoter capital and, where relevant, strategic or customer-linked funding.

QUESTIONS WORTH ASKING
• Which anchor ecosystems are most relevant to our product and capabilities?
• Which certifications or customer approvals would prevent us from qualifying today?
• Can the balance sheet support capacity before the first large order is fully secured?
• Who owns the qualification programme inside the company — beyond the promoter?

DANTAYA’S VIEW
The opportunity is not available to every manufacturer. It will favour businesses that can make themselves easy to qualify, easy to finance and dependable at scale. The strategic work starts before the RFQ, not after it.